

5 May 2023

Usage of Biologic and Biosimilar Products within Rheumatology

1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

• Abatacept [Orencia]	IV 59	SC 181
• Adalimumab [Humira]	405	
• Adalimumab Biosimilars	Amgevita 139	Imraldi 616
• Apremilast [Otezla]	33	
• Baricitinib [Olumiant]	48	
• Certolizumab [Cimzia]	121	
• Etanercept [Enbrel]	129	
• Etanercept Biosimilars	Benepali 345	
• Filgotinib [Jyseleca]	<5	
• Golimumab [Simponi]	101	
• Guselkumab [Tremfya]	8	
• Infliximab [Remicade]	51	
• Infliximab Biosimilars	IV Remsima 47	SC <5
• Ixekizumab [Taltz]	84	
• Risankizumab [Skyrizi]	<5	
• Rituximab [MabThera]	74	
• Rituximab Biosimilars	Truxima 198	
• Sarilumab [Kevzara]	<5	
• Secukinumab [Cosentyx]	238	
• Tocilizumab [Ro Actemra]	IV 49	SC 140
• Tofacitinib [Xeljanz]	26	
• Upadacitinib [Rinvoq]	84	
• Ustekinumab [Stelara]	14	

2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis ONLY in the last 3 months with the following drugs?

• Adalimumab [Humira]	<5	
• Adalimumab Biosimilars	Imraldi <5	Amgevita <5
• Certolizumab [Cimzia]	<5	
• Etanercept [Enbrel]	<5	
• Etanercept Biosimilars	<5	
• Golimumab [Simponi]	<5	

5 May 2023

- Infliximab [Remicade] <5
- Infliximab Biosimilars <5
- Ixekizumab [Taltz] <5
- Secukinumab [Cosentyx] <5
- Tofacitinib [Xeljanz] <5
- Upadacitinib [Rinvoq] <5

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.